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The development of next-generation sequencing (NGS) technologies are revolutionizing medical practice, facilitating more
accurate, sophisticated and cost-effective genetic testing. NGS is already being implemented in the clinic assisting diagnosis
and management of disorders with a strong heritable component. Although considerable attention has been paid to issues
regarding return of incidental or secondary ﬁndings, matters of consent are less well explored. This is particularly important for
the use of NGS in minors. Recent guidelines addressing genomic testing and screening of children and adolescents have
suggested that as ‘young children’ lack decision-making capacity, decisions about testing must be conducted by a surrogate,
namely their parents. This prompts consideration of the age at which minors can provide lawful consent to health-care
interventions, and consequently NGS performed for diagnostic purposes. Here, we describe the existing legal approaches
regarding the rights of minors to consent to health-care interventions, including how laws in the 28 Member States of the
European Union and in Canada consider competent minors, and then apply this to the context of NGS. There is considerable
variation in the rights afforded to minors across countries. Many legal systems determine that minors would be allowed, or may
even be required, to make decisions about interventions such as NGS. However, minors are often considered as one single
homogeneous population who always require parental consent, rather than recognizing there are different categories of ‘minors’
and that capacity to consent or to be involved in discussions and decision-making process is a spectrum rather than a hurdle.
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INTRODUCTION
The rapid development of next-generation sequencing (NGS) tech-
nologies (ie, new high-throughput and massively parallel DNA
sequencing) has substantially reduced both the cost and the time
required to sequence an entire human genome or exome. This
development is likely to change the current practice of medicine by
facilitating more accurate, sophisticated and cost-effective genetic
testing.1 Implementation of NGS is already aiding the diagnosis and
management of disorders that have a strong heritable component,
such as rare diseases,2 cardiological conditions3 and cancers.4 In
addition, NGS is predicted to greatly increase personalized medicine
possibilities in the future, including diagnosis of complex disorders,
drug therapies and treatments.
This technological development is likely to be particularly relevant
for rare diseases in the pediatric population. The low prevalence
worldwide makes diagnosis of these rare diseases extremely challen-
ging for clinicians, and let alone for scientiﬁc researchers to determine
their etiology. Children with rare diseases have a high mortality and
morbidity rate, with 30% dying in the ﬁrst year of life.5 Although a
rare disease may only affect a small number of children, when pooled,
rare diseases represent a signiﬁcant burden to the health-care system.
Therefore, early diagnosis and swift access to appropriate treatment
are of key importance for both the families and the medical system
overall. Implementation of NGS in routine diagnostics would help
diagnose pediatric conditions of presumed genetic origin more rapidly
and more efﬁciently,6–8 and greatly increase the overall diagnostic
yield.9,10
Yet, the large amount of information that is generated about a
patient through the use of NGS has led technology users, medical
professionals, ethicists and other stakeholders to question what kind of
information should be returned to the families. NGS generates a wide
range of results: some are validated and clinically useful; others are
validated, but not associated with any known treatment or preventive
measure; and ﬁnally, others are of unclear or unknown signiﬁcance.
NGS may also identify incidental ﬁndings or mutations that are linked
to conditions unrelated to the original diagnostic question. These
ﬁndings may identify a range of unexpected information, such as the
patient’s susceptibility to develop diseases, their ability to respond to
different treatments or their carrier status for a recessive disease. This
information may be of interest to the patients for their own health or
future reproductive choices or alternatively to other family members.
Determining which results and incidental ﬁndings should be
returned following NGS for diagnostic purposes in minors poses
additional challenges. The status of minors requires that a parent or
the legal guardian be the primary decision maker. Deciding on behalf
of children which incidental ﬁndings should (or should not) be
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communicated to the family removes the child's opportunity to be
able to make an informed choice about which genetic information he
or she wants to know (or not to know), once they develop the capacity
to do so. As results will usually be returned to the child’s parents, this
question also leads to debates about the responsible management of
the pre- and post-test counseling processes, and the impact of the
information on the parents, the children and the family as a whole.
NGS has the potential to incidentally identify information about
one's genetic risk for late-onset conditions, some of which may be
without prevention or treatment options.11–14 Although this informa-
tion may not be immediately relevant to the health of the child, it may
be of direct importance to the health of family members. Therefore, it
is essential to analyze to what extent minors and/or parents can
consent to NGS, and more speciﬁcally, to the return of incidental or
secondary results. To date, a large part of the debate about the use of
NGS in minors has concentrated on which results and secondary
ﬁndings should (or should not) be returned.15–16 Although NGS is
increasingly in use in the clinic, little attention has been paid to the
speciﬁc consent issues with respect to minors.
The recent 2015 Position Statement on the ethical, legal and
psychosocial implications of genetic testing in children and adolescents
of the American Society of Human Genetics (ASHG) has described
informed consent to genetic and genomic testing as a core principle
for which there are few exceptions. They add that ‘[y]oung children
lack decision-making capacity, so decisions about testing must be
conducted through surrogates, usually the parents, and must be done
with the child’s best interest at heart’ [our emphasis]. In light of this,
our question is whether, and from what age, minors can provide
lawful consent to health-care interventions and, consequently, NGS-
related decisions. In this article, we aim to describe various existing
legal approaches regarding the rights of minors to consent to health-
care interventions. We then apply this to the context of NGS.
METHODOLOGY
To address this question, we described how laws in the 28 Member States of the
European Union and Canada consider competent minors. The national
legislations were identiﬁed by consulting websites of governmental agencies,
and databases such as HumGen International, N-Lex and CanLII. If the
legislation had no ofﬁcial English translation, an unofﬁcial translation and
analysis of the legal disposition were validated by local legal experts. We
interrogated these documents using the following questions: What are the rights
of minors to consent to health-care interventions, notably to NGS-related
decisions? Can minors provide lawful consent and, if so, from what age?
In this paper, we deﬁne a minor as an individual who has not yet attained the
age of legal majority under regional or national law and has not been declared
emancipated. Emancipated minors are those who have achieved independence
from their parents, through marriage, by entering military service or by court
order. In a separate article, we have described the rights of minors to consent to
living organ donation, and compared those with legislation addressing general
health-care interventions.17
RESULTS
Our analysis demonstrates that there is little uniformity regarding the
legal capacity to consent. The legislation on health-care decision-
making varies between countries and often even between regions and
provinces within those countries.
Capacity to consent presumed with legal majority
In general, adults are presumed to have the capacity to consent
(although the presumption is rebuttable). Thus, when a minor reaches
the legal age of majority, the capacity to consent is presumed. The age
of majority is legally ﬁxed and may vary according to domestic law
(see Table 1). The most commonly used age of majority is 18 years,
such as in most parts of the European Union, as well as in various
Canadian provinces (Alberta, Manitoba, Ontario, Prince Edward
Island, Québec, Saskatchewan). However, some regions use alternative
demarcations, such as 16 years (eg, Scotland) or 19 years (eg, the
Canadian provinces of British Columbia, New Brunswick, Newfound-
land and Labrador, Northwest Territories, Nova Scotia, Nunavut and
Yukon Territory).
Competent minors and the capacity to consent to health-care
decision
Legal frameworks adopt various approaches to determine the extent to
which minors are legally capable to consent to health care and to make
their own health-care decisions. These approaches are dictated by law
or, when no statutory legislation exists, by common law. We identiﬁed
three different approaches in the regions we studied: (i) consent by
minors for health-care decisions from a ﬁxed age onwards;
(ii) competence assessment-based consent; and (iii) a mixed
approach where ﬁxed age limits are combined with competence-
based approaches. Table 2 provides an overview of the different
approaches to legal capacity in different regions. Supplementary Table
1 provides reference to the relevant legislations.
Legally ﬁxed age for capacity to consent. Some laws state a ﬁxed age at
which an individual is considered capable of providing consent alone
to medical care. This age usually differs from the legal age of majority.
However, in some countries, such as France18,19 and Greece,20 the age
of legal capacity to consent to medical interventions usually coincides
with the age of legal majority. Before that age, health-care interven-
tions should take place with the consent of the parents and the assent
of the minor should be sought, if he or she is capable of expressing his
or her will and of participating in the decision.
When the ﬁxed age of capacity to consent to medical care differs
from the age of legal majority, it is often set at 16 years. For example,
the Dutch law stipulates that ‘a minor who has reached the age of 16
years is capable of entering into a treatment agreement for his own
beneﬁt, and to perform legal acts that are immediately related to the
agreement.’21 Thus, under a legally ﬁxed age approach, minors are
presumed to be competent to give consent to medical treatment at the
legally ﬁxed age.
Some regions also use a ﬁxed age approach, but with additional
conditions or exceptions. This is the case in the province of Québec
(Canada), where consent can be given directly by patients from 14
years onward. However, the person with parental authority or
guardianship must be informed if the minor is required to remain
in a health or social services establishment for more than 12 hours.22
In Bulgaria, dual consent to medical interventions is necessary when a
minor is aged between 14 and 18 years. Thus, from such a minor,
consent should be sought, together with the consent of the parent (or
legal representative).23 Dual consent is also required in Poland when
the minor is more than 16 years old.24 In Spain, where the age to
consent to health-care is ﬁxed at 16 years, consent shall nevertheless be
provided by the legal representative if the minor is not intellectually or
emotionally capable of understanding the scope of the intervention.
However, the opinion of the minor will need to be taken into
consideration from the age of 12 years onward.25 The law also requires
that if, according to the physician, the intervention entails a serious
risk, the parents are to be informed and their opinion is to be taken
into account.
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Competence-based approaches. In certain countries, the law refers
solely to a competence-based approach to evaluate the capacity of
children to consent to medical interventions, regardless of their age.
Rather than considering only the age of the child, the competence-
based assessment considers the capacity of minors to make informed
decisions through a case-by-case analysis of their cognitive and
psychosocial maturity and their capacity to understand. Minors who
are considered to possess the same capacity as competent adults are
thereby legally authorized to provide free and informed consent.
For example, in Canada, several provincial laws stipulate that
minors can consent to their own medical care if they are
deemed ‘capable’ of doing so (eg, Ontario,26 Prince Edward Island,27
Yukon28). There is no set age when a child is deemed capable. The law
generally considers them capable if they understand the need for the
Table 2 General approach towards capacity to consent of minors
Legally ﬁxed age for capacity to consent to medical
interventions Competence-based approach Mixed approaches
Canada Newfoundland and Labrador, Quebec Alberta, Nova Scotia, Northwest Territories, Nuna-
vut, Saskatchewan, Ontario, Prince Edward Island,
Yukon
British Columbia, Manitoba, New
Brunswick
European Union Bulgaria, Croatia, Cyprus, France, Greece, Hungary, Italy,
Netherlands, Poland, Portugal, Slovakia, Spain, Sweden,
United Kingdom (England & Wales)
Belgium, Czech Republic, Estonia, Finland, Ger-
many, Luxembourg
Denmark, Latvia, Lithuania, Romania,
Slovenia, United Kingdom (England
& Wales)
Table 1 General approach regarding majority
Legally ﬁxed age
(o18 years) Legally ﬁxed age (18 years) Legally ﬁxed age (19 years)
Canada Albertaa, Manitobab, Ontarioc, Prince Edward Islandd, Québece,
Saskatchewanf
British Columbiag, New Brunswickh, Newfoundland
and Labradori, Northwest Territoriesj, Nova Scotiak,
Nunavutl, Yukonm
European Union United Kingdom
(Scotland) (16 years)n
Austriao, Belgiump, Bulgariaq, Croatiar, Czech Republics, Cyprust, Den-
marku, Estoniav, Finlandw, Francex, Germanyy, Greecez, Hungaryaa, Italyab,
Latviaac, Lithuaniaad, Luxembourgae, Netherlandsaf, Polandag, Portugalah,
Romaniaai, Slovakiaaj, Sloveniaak, Spainal, Swedenam, United Kingdom
(England & Wales)an
aCanada. Alberta. Age of Majority Act. s. 1. https://www.canlii.org/en/ab/laws/stat/rsa-2000-c-a-6/latest/rsa-2000-c-a-6.html. Accessed: August 2015.
bCanada. Manitoba. The Age of Majority Act. s. 1. https://web2.gov.mb.ca/laws/statutes/ccsm/a007e.php. Accessed: August 2015.
cCanada. Ontario. Age of Majority and Accountability Act. s. 1. http://www.ontario.ca/laws/statute/90a07. Accessed: August 2015.
dCanada. Prince Edward Island. Age of Majority Act. s. 1. https://www.canlii.org/en/pe/laws/stat/rspei-1988-c-a-8/latest/rspei-1988-c-a-8.html. Accessed: August 2015.
eCanada. Quebec. Civil Code of Québec. s. 133. http://www2.publicationsduquebec.gouv.qc.ca/dynamicSearch/telecharge.php?type=2&ﬁle= /CCQ_1991/CCQ1991_A.html. Accessed: August 2015.
fCanada. Saskatchewan. The Age of Majority Act. s. 2 (1). http://www.publications.gov.sk.ca/details.cfm?p=393. Accessed: August 2015.
gCanada. British Columbia. Infants Act. s. 17. http://www.canlii.org/en/bc/laws/stat/rsbc-1996-c-223/latest/. Accessed: August 2015.
hCanada. New Brunswick. Age of Majority Act. s. 1 (1). https://www.canlii.org/en/nb/laws/stat/rsnb-2011-c-103/latest/rsnb-2011-c-103.html. Accessed: August 2015.
iCanada. Newfoundland and Labrador. Age of Majority Act. s. 2 (a). http://www.assembly.nl.ca/legislation/sr/annualstatutes/1995/A04-2.c95.htm. Accessed: August 2015.
jCanada. Northwest Territories. Age of Majority Act. s. 2. https://www.canlii.org/en/nt/laws/stat/rsnwt-1988-c-a-2/latest/rsnwt-1988-c-a-2.html. Accessed: August 2015.
kCanada. Nova Scotia. Age of Majority Act. s. 2 (1). http://nslegislature.ca/legc/statutes/agemajor.htm. Accessed: August 2015.
lCanada. Nunavut. Age of Majority Act. s. 2. https://www.canlii.org/en/nu/laws/stat/rsnwt-nu-1988-c-a-2/latest/rsnwt-nu-1988-c-a-2.html. Accessed: August 2015.
mCanada. Yukon. Age of Majority Act. s. 1 (1). http://www.gov.yk.ca/legislation/acts/agma.pdf. Accessed: August 2015.
nUnited Kingdom. Scotland. Age of Legal Capacity (Scotland) Act 1991. s. 1 (1). http://www.legislation.gov.uk/ukpga/1991/50/contents. Accessed: August 2015.
oAustria. Civil Code (Allgemeines Bürgerliches Gesetzbuch). s. 21 (2). https://www.jusline.at/Allgemeines_Buergerliches_Gesetzbuch_%28ABGB%29_Langversion.html. Accessed: August 2015.
pBelgium. Civil Code (Burgerlijk Wetboek). s. 488. http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&table_name=wet&cn=1804032130. Accessed: August 2015.
qBulgaria. Act on Persons and Family (ЗАКОН ЗА ЛИЦАТА И СЕМЕЙСТВОТО). s. 2. http://lex.bg/bg/laws/ldoc/2121624577. Accessed: August 2015.
rCroatia. Family Act (Obiteljski zakon). s. 117 (2). http://narodne-novine.nn.hr/clanci/sluzbeni/2014_06_75_1404.html. Accessed: August 2015.
sCzech Republic. Civil Code (občanský zákoník). s. 30 (1). http://www.czechlegislation.com/en/89-2012-sb. Accessed: August 2015.
tCyprus. Children Law (Ο Περί Παίδων Νόμος του). s. 2. http://www.cylaw.org/nomoi/indexes/352.html. Accessed: August 2015.
uDenmark. Act on Guardianship (Lov om vergemål). s. 8. https://lovdata.no/dokument/NL/lov/2010-03-26-9. Accessed: August 2015.
vEstonia. General Principles of the Civil Code Act (Tsiviilseadustiku üldosa seadus). s. 8 (2). https://www.riigiteataja.ee/akt/106122010012. Accessed: August 2015.
wFinland. Child Custody and Visiting Rights (Laki lapsen huollosta ja tapaamisoikeudesta). s. 3 (2). https://www.ﬁnlex.ﬁ/ﬁ/laki/ajantasa/1983/19830361. Accessed: August 2015.
xFrance. Civil Code (Code civil). s. 388. http://www.legifrance.gouv.fr/afﬁchCode.do?cidTexte=LEGITEXT000006070721. Accessed : August 2015.
yGermany. Civil Code (Bürgerliches Gesetzbuch). s. 2. http://www.gesetze-im-internet.de/englisch_bgb/englisch_bgb.html. Accessed: August 2015.
zGreece. Civil Code (Αστικός Κώδικας). s. 127. http://www.ministryofjustice.gr/site/kodikes/%CE%95%CF%85%CF%81%CE%B5%CF%84%CE%AE%CF%81%CE%B9%CE%BF/%CE%91%CE%
A3%CE%A4%CE%99%CE%9A%CE%9F%CE%A3%CE%9A%CE%A9%CE%94%CE%99%CE%9A%CE%91%CE%A3/tabid/225/language/el-GR/Default.aspx. Accessed: August 2015.
aaHungary. Civil Code (2013 évi V. törvény a Polgári Törvénykönyvről). s. 2:10 (1). http://njt.hu/cgi_bin/njt_doc.cgi?docid=159096. Accessed: August 2015.
abItaly. Civil Code (Codice Civile). s. 2. http://www.normattiva.it/uri-res/N2Ls?urn:nir:stato:decreto.regio:1942-03-16;262!vig= . Accessed: August 2015.
acLatvia. Civil Code (Civilikums). s. 219. http://likumi.lv/doc.php?id=90224. Accessed: August 2015.
adLithuania. Civil Code (Lietuvos Respublikos civilinis kodeksas). s. 2.5 (1). http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=245495. Accessed: August 2015.
aeLuxembourg. Civil Code (Code Civil). s. 488. http://www.legilux.public.lu/leg/textescoordonnes/codes/code_civil/CodeCivil_PageAccueil.pdf. Accessed: August 2015.
afNetherlands. Civil Code (Burgerlijk Wetboek). s. 233. http://www.wetboek-online.nl/wet/Burgerlijk%20Wetboek%20Boek%201.html. Accessed: August 2015.
agPoland. Civil Code (Kodeks cywilny). s. 10 (1). http://isap.sejm.gov.pl/DetailsServlet?id=WDU19640160093. Accessed: August 2015.
ahPortugal. Civil Code (Código Civil). s. 130. http://www.pgdlisboa.pt/leis/lei_mostra_articulado.php?nid=775&tabela= leis. Accessed: August 2015.
aiRomania. Law 287/2009 on the Civil Code (Legea 287/2009 privind Codul Civil). s. 38 (2). http://www.cdep.ro/pls/legis/legis_pck.htp_act?ida=90254. Accessed: August 2015.
ajSlovakia. Civil Code (Občanský zákoník). s. 8 (2). http://www.zakonypreludi.sk/zz/1964-40. Accessed: August 2015.
akSlovenia. Law on Marriage and Family Relations (Zakon o zakonski zvezi in druzinskih razmerjih). s. 117 (1). http://www.mddsz.gov.si/ﬁleadmin/mddsz.gov.si/pageuploads/dokumenti__pdf/
zakonodaja/law_on_marriage_and_family_relations.pdf. Accessed: August 2015.
alSpain. Civil Code [Código Civil]. s. 315. http://www.boe.es/buscar/act.php?id=BOE-A-1889-4763. Accessed: August 2015.
amSweden. Parental Code (Föräldrabalk). s. 6 (2). http://www.riksdagen.se/sv/Dokument-Lagar/Lagar/Svenskforfattningssamling/Foraldrabalk-1949381_sfs-1949-381/. Accessed: August 2015.
anUnited Kingdom. England & Wales. Family Law Reform Act 1969. s. 1 (1). http://www.legislation.gov.uk/ukpga/1969/46. Accessed: August 2015.
Legal approaches for health-care decision in minors
K Sénécal et al
3
European Journal of Human Genetics
medical treatment in question, what the treatment involves, and the
beneﬁts and risks if they receive – or do not receive – treatment.
Various European countries, such as Belgium,29 the Czech Republic,30
Estonia,31 Finland32 and Luxembourg,33 have adopted a similar system
in which health-care professionals are responsible for evaluating the
competence and maturity of a minor on a case-by-case basis.
In addition, when there is no statutory legislation addressing the
capacity of minors to consent, a similar competence-based assessment
approach is applied based on common law principles. According to
common law, a minor who can understand and appreciate the nature
and consequences of his or her decision and its alternatives is able to
give valid consent, regardless of age. This is the case in three Canadian
provinces (Alberta, Saskatchewan, Nova Scotia)34 and in Scotland.35
Courts are usually ﬂexible in deciding if a child is capable, depending
on how mature the child is and how grave the medical treatment. For
example, a very young child may be able to consent to the dressing of
a wound. On the other hand, an older child may not be deemed
capable to refuse life-saving treatment. In this regard, it is worth
mentioning that, in situations where a health-care intervention might
not be in the child’s best interests, that child’s decision might be
overruled. Similarly, a parent refusal may be overturned.
Mixed approaches. Some regions have adopted legislation combining
a legally ﬁxed age and an ad hoc maturity assessment of minors. For
example, in Manitoba36,37 and New Brunswick38 (Canada), a minor
between 16 and 18 years has full ‘legal’ capacity and can make all
health-care decisions, whereas to younger children, the competence-
based approach applies. Nevertheless, some legislation places other
limitations on recognition of the capacity of the minor to give consent.
An example of this is in New Brunswick (Canada) where the law
speciﬁes that the consent of a minor who has not attained the age of
16 years to give medical treatment is (in the opinion of a legally
qualiﬁed medical practitioner) as effective as if he had attained the age
of majority under the following conditions: (i) the minor is capable of
understanding the nature and consequences of a medical treatment;
and (ii) the medical treatment and the procedure to be used are in the
best interests and his continuing health and well-being of the minor.38
The law of British Columbia (Canada) also speciﬁes that the health-
care provider should be satisﬁed that the minor understands the
nature, consequences, beneﬁts and risks of the health-care; and should
have made reasonable efforts to determine and conclude that the
health care is in the minor's best interests.39
Similarly, in Latvia,40 a minor patient from the age of 14 years can
consent to medical treatment but, if the minor refuses to give his
consent for medical treatment and according to the physician, the
treatment is in the interests of this patient, the consent shall be given
by the lawful representative of the minor patient.
DISCUSSION
Our analysis showed that there is considerable variation in the rights
afforded to minors across countries and legislation. Although the age
of legal majority is relatively standardized, countries adopt different
approaches to determine the extent to which minors are capable of
providing consent to health-care interventions and to make their own
health-care decisions. These approaches are relevant when discussing
decisions regarding the implementation of NGS in pediatric situations.
When adult relatives of an affected individual are at risk of a disorder,
both can decide for themselves whether or not to undergo a genetic
test. However, in the case of at-risk incompetent minors, this decision
will be made by others, most often the parents. As minors are not
entitled to decide for themselves, all health-care decisions affecting
these minors should be addressed with particular caution. Thus, the
2015 ASHG Position Statement41 recognizes ‘as children age, they gain
decision-making capacity and experience with health conditions.
Therefore, including children to various degrees as they age in
genetic-and genomic- testing decisions and responses is important
but challenging. [Also,] because children are young, decisions for them
and by them might have implications for the course of their lives’.
Parents are morally and legally responsible for their children and are
given authority to make decisions on their behalf, taking into
consideration their best interests. This standard of ‘best interests’ has
become a central component and a tool to guide ethical and legal
discussions about children in the area of medicine, in both the
literature42–44 and in national and international normative
documents.45,46 In the context of genetic testing, there are many
different views regarding what is in the child’s best interests. This
debate has arisen in discussions regarding predictive genetic testing
and carrier testing in minors, particularly whether parents have the
authority to request this testing for their children.47–48 On one hand,49
some authors have suggested that parents are the most informed
judges of what is in their child’s best interests and that they should
therefore be afforded the right and authority to decide for their
children.50 On the other hand, some have stressed that health-care
professionals are not required to comply with parental requests. They
argue that health-care professionals have a duty to promote the well-
being of children and should override parental decisions that have
signiﬁcant potential to adversely impact the health or well-being of the
child.51
A similar debate arose recently in response to the American College
of Medical Genetics and Genomics (ACMG) guidelines52 regarding
the duty to hunt for secondary variants outside the primary scope of
an NGS analysis. The ACMG developed a list of 56 genes associated
with 24 inherited conditions (with both early and late onset) that
should be reported when a patient, regardless of age, undergoes NGS
testing. The rationale for what has been called ‘opportunistic screen-
ing’ is based on the view that this could lead to medical beneﬁt for the
patient and their family. When testing is performed in children, the
ACMG argues that identiﬁcation of such pathogenic variants could
beneﬁt the child by providing important health information, enabling
preventive or therapeutic interventions. In addition, this information
could beneﬁt the parents by informing them about potential heritable
conditions within themselves before symptoms manifest. Hence, the
ACMG considered ‘that the ethical concerns about providing children
with genetic risk information about adult-onset diseases were out-
weighed by the potential beneﬁt to the future health of the child and
the child’s parent of discovering an incidental ﬁnding where inter-
vention might be possible’.52 Furthermore, the ACMG considers it
unethical for laboratories not to report such secondary variants,
because it prevents parents from acting in their child’s best interests
and avoiding preventable harm.16,53 This obligatory ‘duty to hunt’ by
genetic laboratories has received considerable criticism and authors
have highlighted the lack of scientiﬁc evidence on which the selection
of the ACMG’s list of secondary variants is based, the potentially
inappropriate and costly medical follow-up required if variants are
classiﬁed as pathogenic, and the time and resources necessary to
perform this ‘opportunistic screening’.54,55 Although the original
ACMG recommendations stated that analysis of these 56 genes should
be mandatory, criticisms highlighting the importance of respecting
patient autonomy and the patients’ right not to know have led to an
amendment in their policy, allowing parents to opt out from receiving
those results for themselves and for their children.54 Yet, parental
decisions to receive or not receive these results may have different
Legal approaches for health-care decision in minors
K Sénécal et al
4
European Journal of Human Genetics
outcomes for the child. As noted above, the ASHG adopted a more
nuanced approach.41 They recognized that, although in general parents
should be able to decline to receive secondary ﬁndings in advance of
genetic testing, there are possible exceptions. Thus, where there is
strong evidence that a secondary ﬁnding has urgent and serious
implications for a child’s health or welfare, and effective action can be
taken to mitigate that threat, the ASHG recommends that the clinician
communicates those ﬁndings to the parents or guardians, regardless of
the general preferences stated by the parents.
In debates around the use of NGS in the pediatric population,
insufﬁcient attention has been paid to minors and their capacity, or
not, to be involved in decisions around NGS. Our analysis of various
legislation showed that many legal systems determine that minors are
allowed, or may even be required, to make decisions about interven-
tions such as NGS, based either on the fact that they have reached the
age of legal majority or that they have sufﬁcient capacity to make such
decisions. It should be noted, however, that if the NGS tests in
question are considered to be research, the legal framework surround-
ing the health care of minors may not apply. Indeed, NGS has resulted
‘in a rapid evolution of research practices towards a process whereby
suitable patients (usually with either cancer or a rare genetic disease)
are referred by clinicians into genome sequencing research programs.
However, rather than being driven mainly by a hypothesis-driven basic
discovery motive, the goal is increasingly patient-focused and intended
to ﬁnd information of clinical beneﬁt to the participant, indeed
blurring the lines between ‘patient’ and ‘research participant’.56
As well explained by authors Lyon and Segal,56 although this shift
from the research setting to the clinic could have a positive impact for
the patient, this changing landscape also begs for an in-depth
discussion of the ethical and regulatory issues that face genomics
research and genomic medicine.
In addition to the various legal approaches regarding the capacity of
minors to consent and the different ﬁxed age they are considered to be
capable to give consent, the diversity is at least as great, if not more,
when considering the capacity of minors to consent in a research
context. Effectively, in their legal frameworks, some countries either
do not differentiate between capacity to consent to health care or to
research or are silent as to the required age (or criteria) of consent for
participating in research, compared with others who do make this
distinction (eg, Quebec (Canada)). Thus, in addition to the variety of
approaches taken regarding the capacity to consent to health-care and
the different ﬁxed age or criteria to be considered ‘capable’, researchers
also have to add to this puzzle the difﬁculty of establishing whether
different rules apply or not with regards to the capacity to consent
to research and, if so, which one. Indeed, some norms governing
research will vary according to the level of risks associated with
the research project. In a context where transnational and inter-
national research become more and more frequently the norm, such
as in rare diseases research, this diversity of approaches presents
signiﬁcant difﬁculty for researchers in determining the capacity for
minors to give consent. In practice, it could be challenging to identify
the legal framework applicable or to have the appropriate policy for
each country or jurisdiction.
Moreover, various laws emphasize that health-care professionals
should not only involve children and adolescents who are legally
capable to give consent to participate in the decision-making process,
but should also encourage the involvement of all pediatric patients,
regardless of whether they are considered legally competent. Indeed,
the United Nations Convention on the Rights of the Child (1989) asserts
that children have the right to express their views freely in all matters
affecting them and to have their opinions taken into account (art. 12).
This supports that the growing levels of capacity to consent need to be
taken seriously.
CONCLUSION
In the decision-making process and the consent procedures regarding
the pediatric use of NGS, the opinion of minors should be taken into
consideration as an increasingly determining factor in proportion to
their age and degree of maturity. As we have demonstrated, certain
minors do have the legal capacity to consent to the use of NGS and to
make decisions about receiving incidental NGS results. Although they
are often referred to as one single homogeneous population who
always require parental consent, there are different categories of
‘minors’ and an amalgam of ‘capacity’: some minors are legally
capable to consent to health-care decisions, some are capable to be
involved in the decision-making process and others are legally capable
or in some countries even required to participate in discussions and
the decision-making process.
As we demonstrated, there are currently different categories of
‘minors’ and an amalgam of ‘capacity’, depending on the legal
approach adopted by regional or local legislations. In addition, this
amalgam becomes even greater when we extend the breach to take
into account the speciﬁc rules that govern the research context.
As genomic sequencing of children for health-care purposes
and research often become intertwined activities,57 relevant nor-
mative frameworks, including consent to health-care and research,
as well as the return of NGS results, need to be carefully and
critically analyzed and, if necessary, adapted to the contemporary
situation (ie, blurred line between clinical and research context).
Also, the need for international research collaborations (eg, for rare
diseases research or pediatric cancer) call for a harmonization of
the norms.
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